Adenosine Injection
NDC Package 84549-031-67

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Adenosine injection is uSP is indicated for the following:Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). This formulation utilizes a injection delivery system. Marketed by Propharma Distribution, this product is identified by NDC 84549-031 and is authorized under FDA application ANDA077283.

Identification & Billing

NDC Package Code
84549-031-67
Package Description
2 mL in 1 SYRINGE
Product Code
84549-031
11-Digit Billing Format
84549003167
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Adenosine
Non-Proprietary Name
Adenosine
Substance Name
Adenosine
Dosage Form
Injection - A sterile preparation intended for parenteral use; five distinct classes of injections exist as defined by the USP.
Administration Route
Intravenous - Administration within or into a vein or veins.
Active Ingredient(s)
ADENOSINE 3 mg/mL
Pharmacologic Class
Usage Information
Adenosine Injection, USP is indicated for the following:Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration.It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration.

Regulatory & Marketing

Labeler Name
Propharma Distribution
Product Type
Human Prescription Drug
FDA Application #
ANDA077283
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-16-2014
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 84549-031-67 identifies a specific commercial package of 2 ml in 1 syringe of Adenosine, a human prescription drug labeled by Propharma Distribution. This injection is formulated for intravenous use and contains adenosine as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Propharma Distribution on April 16, 2014. The current certification is valid through December 31, 2027.

How is this Propharma Distribution product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 84549003167. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
84549-031-67
11-Digit CMS (5-4-2)
84549-0031-67

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.